Yahoo! Finance: XTLB NewsLatest Financial News for XTL BIOPHARMACEUTICANotification of Extraordinary General Meetings and Further Changes to Board Composition (PR Newswire)- August 27, 2008 XTL Biopharmaceuticals Ltd. today announced a notice convening two Extraordinary General Meetings . The Meetings will take place at the Conference Room at the Company's Israeli offices at Building 3, Kiryat Weizmann Science Park, Rehovot, Israel 76100, at 3:00 p.m.http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/080827/clw103.h... XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition (PR Newswire)- August 15, 2008http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/080815/clf028.h... XTL Biopharmaceuticals Announces Appointment of Samuel H. Rudman to Board of Directors (PR Newswire)- August 14, 2008http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/080814/clth092.... XTL Biopharmaceuticals Announces First Half 2008 Financial Results (PR Newswire)- August 14, 2008 XTL Biopharmaceuticals Ltd. , a biopharmaceutical company engaged in the acquisition and development of therapeutics for the treatment of unmet medical needs, particularly diabetic neuropathic pain and hepatitis C, today announced its financial results for the first half ended June 30, 2008.http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/080814/clth033.... XTL Biopharmaceuticals and Presidio Pharmaceuticals Amend License Agreement for Pre-Clinical Hepatitis C Program XTL to Receive Additional $2 Million- August 5, 2008 XTL Biopharmaceuticals Ltd. announced today an amendment to its licensing agreement with Presidio Pharmaceuticals, Inc. for its pre-clinical program in Hepatitis C focused on the NS5A target.http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/080805/cltu066.... |